Marcus H. Snow, MD, Assistant Professor of Rheumatology, University of Nebraska, discusses the use of biosimilar treatments in children.
Transcript:
Are there special considerations when using biosimilars in children?
Generally, no. Ultimately, in the pediatric realm, we end up having a lot of extrapolation of data and the biosimilars with the pediatric population should not be; ideally, this would be studied as much as it is in the adult world, but we just do not have that as often.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
February 26th 2023On this episode of Not So Different, Vizient’s Carina Dolan, PharmD, MS, BCOP, expounds on some of the results from Vizient’s recent edition of its Pharmacy Market Outlook Report, including how inflation could influence biosimilar utilization.
Retrospective Study Supports Safety of Anti-TNF Biosimilars During Pregnancy
March 18th 2023More and more women are becoming pregnant while on anti–tumor necrosis factor (TNF) biosimilars used to treat inflammatory disorders. However, there is “little data” on the safety and effectiveness of biosimilars in pregnancy, according to authors of a recent retrospective study.
2 Clarke Drive
Cranbury, NJ 08512